XuY, WeiH, GuoQ, et al.The silver tsunami prescription: A comprehensive analysis of approval delays and innovation assessment in China’s novel geriatric drugs (2005–2024). Clin Pharmacol Ther, 2026; 119(1):179–189.
2.
ZhuX, XiaoD. Innovative drugs approved in China after registration classification reform: Current status, disparities, and challenges. Clin Pharmacol Ther, 2026; 119(2):470–479.
3.
AminKS, JainB, WongA, et al.Use of FDA expedited programs and development timelines for new molecular entity drug and new biologic approvals by sponsor experience. Clin Pharmacol Ther, 2026; 119(1):80–83.
4.
HersherM, MervisJ. The great government brain drain. Science (1979), 2026; 391:428–429.
5.
ThorpHH. China turns the tables in biotech. Science, 2026; 391(6784):427.
6.
ArimaM, AtsumiM, TakeuchiK, et al.Perspective of the pharmaceuticals and medical devices agency on drug development for childhood myopia. Clin Pharmacol Ther, 2026; 119(1):26–29.
